BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cardiovascular BioTherapeutics, Inc. (CVBT.OB) Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate


11/13/2008 7:14:26 AM

LAS VEGAS, Nov. 13 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT - News; the "Company") has entered into its first clinical development agreement for its Coronary Heart Disease drug candidate with Cardio Neo-Genesis, LP ("CNG"). The agreement, dated November 11, 2008 states that CNG can fund up to $15,000,000 of the clinical development for the Company's Coronary Heart Disease (CHD) drug candidate. The agreement also provides for a royalty to CNG payable from 5% of CVBT's cash-flow stream on its CHD drug up to 20 times return to CNG's limited partners.

"CVBT is currently utilizing clinical development agreements to fund and advance our drug development candidates," according to Mr. Mickael A. Flaa, CVBT's Chief Financial Officer. Mr. Flaa continued, "Given the stress in the financial markets at this time, we looked to the lessons of history for a strategy to finance CVBT's drug development program. The clinical development arrangements that CVBT has entered into are similar in structure to those used successfully by Amgen, Genentech, Biogen, and others over 20 years ago to fund their drug development programs."

"This development agreement is a positive step in advancing CVBT's CHD drug candidate given today's financial markets," said Mr. Daniel C. Montano, CVBT's CEO. Mr. Montano continued, "I believe that CVBT's existing shareholders will benefit from this new source of funding which does not permanently dilute their shareholdings."

About CardioVascular BioTherapeutics

CVBT (OTCBB: CVBT - News) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit www.cvbt.com.

CardioVascular BioTherapeutics, Inc.

Allison Caplan, (702) 839-7200

acaplan@cvbt.com

Source: CardioVascular BioTherapeutics, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES